

Claims

[Claim 1]. An antibody or antigen binding fragment which binds to TIM-3, optionally isolated, comprising a heavy chain variable region sequence having the sequence of SEQ ID NO:22 and a light chain variable region sequence having the sequence of SEQ ID NO:2.

[Claim 2]. An antibody or antigen binding fragment, optionally isolated, which binds to TIM-3, which is a bispecific antibody or a bispecific antigen binding fragment comprising (i) an antigen binding fragment according to claim 1, and (ii) an antigen binding domain which binds to a target protein other than TIM-3.

[Claim 3]. The antibody, or antigen binding fragment, of claim 2, wherein the antigen binding domain which binds to a target protein other than TIM-3 binds to CD3 or a CD3 polypeptide.

[Claim 4]. An *in vitro* complex, optionally isolated, comprising an antibody, or antigen binding fragment, according to any one of claims 1 to 3 bound to TIM-3.

[Claim 5]. A composition comprising the antibody, or antigen binding fragment, of any one of claims 1 to 3 and at least one pharmaceutically-acceptable carrier.

[Claim 6]. An isolated nucleic acid encoding the antibody, or antigen binding fragment, of any of one of claims 1 to 3.

[Claim 7]. A vector comprising the nucleic acid of claim 6.

[Claim 8]. A host cell comprising the vector of claim 7.

[Claim 9]. A method for making an antibody, or antigen binding fragment, of any of one of claims 1 to 3 comprising culturing the host cell of claim 8 under conditions suitable for the expression of a vector encoding the antibody, or antigen binding fragment, and recovering the antibody, or antigen binding fragment.

~~10. An antibody or antigen binding fragment according to any of one of claims 1 to 3 for use in therapy, or in a method of medical treatment.~~

~~11. An antibody or antigen binding fragment according to any of one of claims 1 to 3 for use in the treatment of cancer, a T-cell dysfunctional disorder, or an infectious disease.~~

~~12. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 3 in the manufacture of a medicament for use in the treatment of cancer, a T-cell dysfunctional disorder, or an infectious disease.~~

[Claim 1310]. A method comprising contacting a sample containing, or suspected to contain, TIM-3 with an antibody or antigen binding fragment according to any one of claims 1 to 3 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

[Claim 1411]. A method of diagnosing a disease or condition in a subject, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment,

according to any one of claims 1 to 3 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

| [Claim 4512]. A method of selecting or stratifying a subject for treatment with a modulator of TIM-3 signalling, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 3 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

| [Claim 4613]. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 3 for the detection of TIM-3 *in vitro*.

| [Claim 4714]. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 3 as an *in vitro* diagnostic agent.

| [Claim 4815]. A method for expanding a population of T cells, wherein T cells are contacted *in vitro* or *ex vivo* with an antibody or antigen binding fragment according to any one of claims 1 to 3.

| [claim 4916]. A chimeric antigen receptor (CAR) comprising an antigen binding fragment according to any one of claims 1 to 3.